Deep Dive

NAD+ and Cellular Longevity

The molecule at the center of aging science—what we know, what we don't, and how to navigate the evidence for supplementation.

📖 40 min read 🔬 47 citations 📅 Updated Feb 2026
Contents
⚠️ Disclaimer

This article is for educational purposes only. NAD+ supplementation is an emerging field with evolving research. Nothing here constitutes medical advice. Consult with a qualified healthcare provider before beginning any supplementation protocol, particularly if you have existing health conditions or are taking medications.

1. Introduction: Why NAD+ Matters

In the past decade, few molecules have captured the attention of longevity researchers, biohackers, and investors quite like NAD+. This coenzyme, present in every living cell, has become central to our understanding of why we age—and potentially, how to slow that process.

The premise is compelling: NAD+ levels decline dramatically with age, and this decline appears causally linked to many hallmarks of aging. Restore NAD+ levels, the theory goes, and you might restore youthful cellular function. It's a hypothesis that has launched multiple clinical trials, several publicly-traded companies, and a supplement market valued in the billions.

But the story is more nuanced than the marketing suggests. While the basic science is sound and increasingly validated, the translation to practical human interventions remains an active area of research with legitimate uncertainties. This guide aims to present the current state of evidence—the strong findings, the unknowns, and the controversies—to help you make informed decisions.

💡 The Core Thesis

NAD+ is a critical coenzyme required for hundreds of enzymatic reactions, including those that regulate cellular energy, DNA repair, and the activity of "longevity proteins" called sirtuins. Its decline with age contributes to metabolic dysfunction, genomic instability, and reduced cellular resilience. Boosting NAD+ may partially reverse these age-related changes—though human evidence is still maturing.

2. The Biology of NAD+

What Is NAD+?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in all living cells. Discovered in 1906 by Arthur Harden and William John Young during their research on fermentation, it took decades to understand its central role in cellular metabolism.[1]

NAD+ exists in two forms: the oxidized form (NAD+) and the reduced form (NADH). Together, they constitute a redox couple that carries electrons in hundreds of metabolic reactions. Think of NAD+ as a molecular taxi, ferrying electrons from one reaction to another, enabling the chemistry of life.

NAD+ in Cellular Metabolism

Glucose → Glycolysis → Pyruvate
↓
NAD+ accepts electrons → becomes NADH
↓
NADH → Electron Transport Chain → ATP (cellular energy)
↓
NADH donates electrons → regenerates NAD+

The Two Roles of NAD+

NAD+ serves two fundamentally different functions in cells, and understanding this distinction is crucial for grasping why it matters for aging:

1. Redox Reactions (Metabolic Role)
As a coenzyme, NAD+/NADH participates in over 400 enzymatic reactions, primarily involving the transfer of electrons in metabolic pathways like glycolysis, the citric acid cycle, and oxidative phosphorylation. In these reactions, NAD+ is not consumed—it cycles between oxidized and reduced forms, carrying electrons.

2. Substrate for NAD+-Consuming Enzymes
This is where the aging connection becomes critical. Several enzyme families actually consume NAD+ as a substrate, breaking it down in the process:

These consuming enzymes create a constant demand for NAD+ synthesis. When NAD+ levels fall, these critical processes suffer—and many of them are directly implicated in aging and age-related disease.

NAD+ Biosynthesis Pathways

Understanding how the body makes NAD+ is essential for understanding supplementation strategies. There are three main biosynthetic pathways:

The Salvage Pathway
Primary NAD+ Source in Mammals

The dominant pathway in most mammalian tissues. When NAD+ is consumed by sirtuins, PARPs, or CD38, it releases nicotinamide (NAM). This nicotinamide is then "salvaged" and recycled back into NAD+ through a two-step process:

Nicotinamide (NAM)
↓ NAMPT (rate-limiting enzyme)
NMN (Nicotinamide Mononucleotide)
↓ NMNAT1-3
NAD+

NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme—it's the bottleneck that controls how quickly NAM can be converted to NMN. Importantly, NAMPT activity declines with age in many tissues.[2]

The Preiss-Handler Pathway
From Dietary Niacin

This pathway synthesizes NAD+ from nicotinic acid (niacin, vitamin B3):

Nicotinic Acid (Niacin)
↓ NAPRT
NAMN
↓ NMNAT1-3
NAAD
↓ NAD synthetase
NAD+

This pathway is particularly active in the liver and may explain why high-dose niacin affects lipid profiles.

The De Novo Pathway
From Tryptophan

The body can synthesize NAD+ from the amino acid tryptophan through the kynurenine pathway. This is a longer, less efficient route that contributes relatively little to total NAD+ synthesis under normal conditions. However, it becomes more significant during inflammation, when kynurenine pathway activity increases.

3. The Age-Related Decline of NAD+

One of the most consistent findings in aging research is that NAD+ levels decline substantially with age. Studies in mice, rats, worms, and humans all demonstrate this pattern, though the magnitude varies by tissue and measurement methodology.

The Evidence for Decline

In a landmark 2013 study, David Sinclair's lab at Harvard showed that NAD+ levels in the muscle tissue of old mice were approximately 50% lower than in young mice.[3] This study also demonstrated that boosting NAD+ with NMN could reverse several age-related markers, sparking intense research interest.

Human studies have confirmed similar trends. A 2015 study measured blood NAD+ metabolites across age groups and found significant correlations between age and reduced NAD+ levels.[4] More recent work has shown tissue-specific variations—some tissues may decline more than others.

📊 Magnitude of Decline

Estimates vary, but research suggests NAD+ levels may decline by 40-50% between ages 40 and 60 in certain tissues. Some researchers estimate that by age 80, NAD+ levels may be only 1-10% of youthful levels—though these extreme estimates are based on limited data and should be interpreted cautiously.[5]

Why Does NAD+ Decline?

The decline isn't due to a single cause but rather reflects the intersection of several age-related changes:

1. Decreased Synthesis
NAMPT, the rate-limiting enzyme of the salvage pathway, decreases in expression and activity with age in multiple tissues. This means the recycling of nicotinamide back to NAD+ becomes less efficient.[6]

2. Increased Consumption by CD38
CD38 is a NAD+-consuming ectoenzyme that increases dramatically with age. In old mice, CD38 levels can be 2-3 times higher than in young mice, and this enzyme is now considered a major driver of age-related NAD+ depletion. CD38 knockout mice maintain youthful NAD+ levels into old age.[7]

3. Increased DNA Damage and PARP Activation
Aging is associated with accumulated DNA damage. PARPs, the enzymes that repair DNA, consume NAD+ as their substrate. More DNA damage means more PARP activity, which depletes the NAD+ pool. This creates a vicious cycle: low NAD+ impairs other repair mechanisms, leading to more damage.[8]

4. Chronic Inflammation ("Inflammaging")
Age-related chronic low-grade inflammation upregulates CD38 expression and activates the kynurenine pathway, both of which deplete NAD+. This connects NAD+ decline to the broader inflammaging phenomenon.

4. Sirtuins, PARPs, and CD38: The NAD+-Dependent Pathways

Understanding why NAD+ matters for aging requires understanding the enzymes that depend on it. Three families dominate the discussion.

Sirtuins: The "Longevity Genes"

Sirtuins are a family of seven enzymes (SIRT1-7 in mammals) that require NAD+ to function. They've been called "longevity genes" because of their profound effects on aging in model organisms—though this framing is now considered somewhat oversimplified.

Sirtuins are deacetylases: they remove acetyl groups from proteins, thereby changing those proteins' activity. Their targets include histones (affecting gene expression), transcription factors, and metabolic enzymes. Key functions include:

Importantly, sirtuin activity is directly limited by NAD+ availability. When NAD+ is low, sirtuins can't function optimally—even if the proteins themselves are present. This means NAD+ depletion could impair all sirtuin-mediated protective mechanisms simultaneously.

The Sirtuin-NAD+ Connection

When sirtuins deacetylate their targets, they break down NAD+ into nicotinamide and O-acetyl-ADP-ribose. The nicotinamide released can then inhibit sirtuin activity (product inhibition) or be recycled back to NAD+ via NAMPT. This creates a tight coupling between NAD+ metabolism and sirtuin activity.

PARPs: DNA Repair and NAD+ Competition

Poly(ADP-ribose) polymerases (PARPs) are enzymes that detect and repair DNA damage. When DNA breaks occur, PARP1 (the most abundant and active family member) binds to the damage site and uses NAD+ to synthesize poly(ADP-ribose) chains, which recruit other repair proteins.

Here's the critical point: PARPs are major NAD+ consumers. Under conditions of significant DNA damage, PARP1 can consume 80-90% of cellular NAD+ within minutes.[10] This massive consumption can:

This PARP-sirtuin competition for NAD+ has important implications. Inhibiting PARP activity can raise NAD+ levels and enhance sirtuin function—which is one reason PARP inhibitors are being explored in aging research (beyond their established use in cancer treatment).

CD38: The Major NAD+ Consumer

CD38 is an ectoenzyme originally studied for its role in immune cell signaling. It's now recognized as one of the largest NAD+ consumers in the body—and perhaps the key driver of age-related NAD+ decline.

CD38 breaks down NAD+ to produce cyclic ADP-ribose (cADPR), a calcium-mobilizing messenger. The problem is that CD38 is extremely inefficient: it hydrolyzes roughly 100 NAD+ molecules for every cADPR produced, essentially "wasting" NAD+.[11]

CD38 expression increases 2-3 fold with age, driven largely by chronic inflammation. Senescent cells, which accumulate with age, secrete inflammatory factors that upregulate CD38 in surrounding tissue. This creates a direct mechanistic link between cellular senescence and NAD+ depletion.

🎯 Therapeutic Implications

The discovery of CD38's role has opened new strategies: rather than just supplementing NAD+ precursors, researchers are exploring CD38 inhibitors that could reduce NAD+ degradation. Compounds like apigenin, quercetin, and 78c (a specific CD38 inhibitor) have shown promise in preclinical studies.

5. Precursors: NMN vs NR vs Niacin

NAD+ itself has poor oral bioavailability—it's largely broken down in the digestive tract before absorption. This has led to interest in precursor compounds that can enter cells and be converted to NAD+ intracellularly. Three main precursors dominate the market and research landscape.

NMN (Nicotinamide Mononucleotide)

Strengths:
  • Direct precursor to NAD+
  • Substantial preclinical data
  • Recent positive human trials
  • Bypasses NAMPT step
Considerations:
  • More expensive than alternatives
  • Uptake mechanism debated
  • Fewer long-term human studies

NR (Nicotinamide Riboside)

Strengths:
  • Most human clinical data
  • Well-established safety profile
  • Patented, quality-controlled supply
  • Clear cellular uptake mechanism
Considerations:
  • Requires conversion to NMN first
  • Variable efficacy in trials
  • Patent restrictions on sourcing

Niacin / NAM

Strengths:
  • Extremely cheap
  • Decades of safety data
  • Proven lipid effects
  • Widely available
Considerations:
  • Flushing side effect (niacin)
  • NAM may inhibit sirtuins directly
  • May not raise NAD+ as effectively

NMN: The Sinclair Protocol

Nicotinamide Mononucleotide (NMN)
Direct NAD+ Precursor
Typical Dose
250-1000mg/day
Bioavailability
Variable
Cost (30 days)
$40-150
Evidence Level
Moderate-Strong

The Science

NMN is one step away from NAD+ in the salvage pathway—it only needs the enzyme NMNAT to be converted. This means it bypasses the rate-limiting NAMPT step, potentially making it more efficient than nicotinamide.

The preclinical data for NMN is extensive. Studies in mice have shown improvements in:[12]

  • Insulin sensitivity and glucose tolerance
  • Mitochondrial function and oxidative metabolism
  • Physical endurance and muscle function
  • Cognitive function and neuronal health
  • Cardiovascular function
  • Age-related gene expression patterns

Human Evidence

Moderate Evidence

Human trials have begun yielding results:

  • Yoshino et al., 2021 (Science): 250mg NMN daily for 10 weeks increased muscle insulin sensitivity in prediabetic postmenopausal women. A landmark trial demonstrating functional metabolic improvements.[13]
  • Igarashi et al., 2022: 250mg NMN daily for 12 weeks improved sleep quality, physical fatigue, and drowsiness in older adults.[14]
  • Kim et al., 2022: 250mg twice daily improved walking speed and grip strength in older men after 12 weeks.[15]

The Uptake Controversy

A scientific debate exists about how NMN enters cells. One view holds that NMN is converted to NR extracellularly before uptake (since NMN is too large to cross membranes easily). However, the 2019 discovery of Slc12a8, a proposed NMN transporter, suggests direct uptake may occur in some tissues—though this transporter's role remains debated.[16] Practically speaking, supplementation studies show NMN raises NAD+ levels regardless of the exact uptake mechanism.

NR: The Patented Precursor

Nicotinamide Riboside (NR)
NAD+ Precursor (via NMN)
Typical Dose
300-1000mg/day
Brand
Niagen® (patented)
Cost (30 days)
$30-80
Evidence Level
Moderate

The Science

NR is converted to NMN by nicotinamide riboside kinases (NRK1/2), then to NAD+ by NMNATs. It's one more step removed from NAD+ than NMN, but has a clearer cellular uptake mechanism via equilibrative nucleoside transporters.

Human Evidence

Moderate Evidence

  • Martens et al., 2018: 1000mg NR daily for 6 weeks raised blood NAD+ by ~60% in healthy older adults. No changes in blood pressure or arterial stiffness were observed.[17]
  • Elhassan et al., 2019: 1000mg NR daily for 21 days increased NAD+ in muscle tissue of older men and reduced inflammatory cytokines.[18]
  • Dollerup et al., 2018: 2000mg NR daily for 12 weeks in obese men did NOT improve insulin sensitivity—a negative trial that tempered initial enthusiasm.[19]

NMN vs NR: The Debate

The "which is better" question is genuinely unresolved. Both raise NAD+ levels effectively. The theoretical arguments favor NMN (fewer conversion steps, potential direct uptake), but NR has more human safety and pharmacokinetic data. Individual response may vary based on tissue-specific expression of transporters and converting enzymes. Some researchers use both.

Niacin and Nicotinamide: The Original B3s

Niacin (Nicotinic Acid) & Nicotinamide
Classical NAD+ Precursors / Vitamin B3
Typical Dose
500-2000mg/day
Cost (30 days)
$5-15
Safety Data
Decades
Evidence Level
Mixed

Niacin (Nicotinic Acid)

Niacin enters NAD+ synthesis via the Preiss-Handler pathway. High-dose niacin (1-3g/day) has been used for decades to improve lipid profiles—raising HDL and lowering LDL and triglycerides. However, recent large trials (AIM-HIGH, HPS2-THRIVE) failed to show cardiovascular benefit when added to statins, dampening enthusiasm for this application.[20]

The main limitation of niacin is the "flush"—a harmless but unpleasant skin flushing and warmth caused by prostaglandin release. Extended-release formulations reduce but don't eliminate this effect.

Nicotinamide (Niacinamide)

Nicotinamide is the salvage pathway substrate and doesn't cause flushing. However, there's a significant concern: at high doses, nicotinamide may inhibit sirtuins directly through product inhibition.[21] This creates a paradox—while nicotinamide can be converted to NAD+, it might simultaneously impair one of the key pathways that makes NAD+ beneficial.

For longevity purposes, most researchers prefer NMN or NR over nicotinamide because of this potential sirtuin inhibition. However, for skin health (UV damage, non-melanoma skin cancer prevention), nicotinamide has good clinical evidence at 500mg twice daily.[22]

Head-to-Head Comparison

Property NMN NR Niacin Nicotinamide
Steps to NAD+ 1 2 4 2
Human NAD+ elevation Yes Yes Likely Yes
Sirtuin activation Expected Expected Unclear May inhibit
Flushing No No Yes No
Cost $$$ $$ $ $
Long-term safety data Limited Moderate Extensive Extensive

6. Practical Supplementation Protocols

Based on current evidence, here are evidence-informed approaches to NAD+ supplementation. These are not medical recommendations—work with a healthcare provider to determine what's appropriate for your situation.

🔬 Conservative Protocol (Evidence-Focused)

For those who want to stay close to what's been tested in clinical trials.

Morning
NMN 250mg OR NR 300mg — with or without food
Doses used in positive human trials
Notes
Start low. Some take sublingual for faster absorption. Monitor for any side effects. Consider periodic breaks (e.g., 5 days on, 2 days off) though no evidence requires this.
⚡ Aggressive Protocol (Biohacker Approach)

Higher doses used by some longevity enthusiasts, including David Sinclair's publicly stated regimen. Less clinical validation at these doses.

Morning
NMN 500-1000mg — often sublingual or mixed into yogurt
Sinclair reports taking 1g daily
Optional
Resveratrol 500-1000mg — with fat (see synergies section)
Theoretical sirtuin-activating synergy
Optional
TMG (Trimethylglycine) 500-1000mg
Methyl donor to support NAD+ metabolism (see below)
⚠️ The TMG Question

NAD+ synthesis and sirtuin activity generate nicotinamide, which must be methylated (by NNMT enzyme) before excretion. This methylation uses methyl groups from SAM (S-adenosylmethionine). Some researchers worry that high-dose NAD+ precursor supplementation could deplete methyl donors, potentially raising homocysteine.

Trimethylglycine (TMG/betaine) is a methyl donor that can replenish the methyl pool. While there's no clinical evidence that NAD+ precursors cause methyl depletion at standard doses, some add TMG as a precaution. Monitor homocysteine levels if concerned.

Timing Considerations

Morning dosing is generally preferred because NAD+ follows circadian rhythms, with levels naturally higher in the morning. There's also theoretical concern that evening supplementation might interfere with the normal NAD+ decline that occurs during sleep (which may be important for circadian regulation), though this hasn't been proven problematic.

Food vs. fasted: NMN and NR appear to be absorbed whether taken with or without food. Some prefer sublingual administration (holding under the tongue) for potentially faster absorption, bypassing first-pass metabolism.

Quality and Sourcing

The NAD+ precursor market has quality control issues. Look for:

7. Synergies with Other Longevity Interventions

NAD+ supplementation doesn't exist in isolation. Research suggests potential synergies with other longevity interventions—though most evidence is preclinical or mechanistic rather than proven in humans.

Exercise: The Proven NAD+ Booster

Exercise naturally increases NAD+ levels through multiple mechanisms:

The relationship works both ways: NAD+ supplementation may enhance exercise performance and recovery. The Yoshino 2021 trial showed NMN improved muscle insulin sensitivity—a metabolic adaptation normally seen with exercise training. Preclinical studies show NMN enhances endurance in aged mice.[24]

✅ Key Point

Exercise is the single most validated intervention for raising NAD+ and improving the metabolic pathways NAD+ supports. Supplementation may be most beneficial as an adjunct to, not replacement for, regular physical activity.

Fasting and Caloric Restriction

Caloric restriction (CR) extends lifespan in nearly every organism tested, and NAD+/sirtuin signaling is a key mediator. Fasting and CR:

This creates potential synergy: NAD+ precursors might enhance the beneficial effects of fasting by ensuring sirtuins have adequate substrate. Some longevity enthusiasts combine intermittent fasting with NAD+ supplementation specifically to amplify sirtuin activation.

Resveratrol: The Sirtuin Activator Hypothesis

Resveratrol, the polyphenol from red wine, gained fame as a potential sirtuin activator. The story is complicated:

The theoretical synergy with NAD+ precursors: resveratrol activates sirtuins (accelerator), while NAD+ provides the necessary substrate (fuel). David Sinclair has long advocated this combination, though clinical evidence for the combined approach is limited.

If using resveratrol, take it with fat (it's lipophilic) to improve absorption. Typical doses are 250-1000mg daily.

CD38 Inhibitors: Reducing NAD+ Consumption

Rather than just supplying more NAD+, another strategy is reducing its degradation by inhibiting CD38. Several natural compounds show CD38-inhibitory activity:

The evidence for these natural CD38 inhibitors raising NAD+ in humans is limited, but they're generally safe and have other potential benefits. Some longevity-focused individuals add quercetin or apigenin to their stack.

Senolytics: Addressing the Root Cause

Senescent cells—damaged cells that have stopped dividing but don't die—accumulate with age and secrete inflammatory factors (the SASP). These factors upregulate CD38 in surrounding tissues, driving NAD+ depletion.

Senolytics are drugs that selectively kill senescent cells. Clearing these cells reduces inflammation and, theoretically, should reduce CD38 expression and preserve NAD+ levels. The combination of senolytics (to reduce the source of inflammation) with NAD+ precursors (to replenish depleted levels) is an emerging area of research.

8. The Controversies and Unknowns

While NAD+ biology is increasingly well-understood, significant uncertainties remain. A responsible assessment must acknowledge these limitations.

The Cancer Question

Perhaps the most significant concern: cancer cells have high metabolic demands and upregulate NAD+ biosynthesis. Could supplying extra NAD+ precursors feed tumor growth?

The evidence is mixed and context-dependent:

⚠️ Current Guidance

Most experts recommend avoiding high-dose NAD+ precursor supplementation if you have an active cancer diagnosis, a history of cancer, or known genetic predispositions to cancer—unless directed by an oncologist. For healthy individuals without cancer risk factors, current evidence doesn't suggest significant concern at standard doses, but long-term data is lacking.

Tissue-Specific Effects

When you take an NAD+ precursor orally, it doesn't distribute equally to all tissues. The liver processes much of the oral dose; how much reaches brain, heart, muscle, or other target organs is incompletely understood.

Different tissues also have different baseline NAD+ levels, different expression of biosynthetic enzymes, and potentially different responses to supplementation. The brain, protected by the blood-brain barrier, may require different strategies than peripheral tissues.

The Long-Term Safety Gap

Human trials have generally been short-term (weeks to months). We don't have long-term randomized controlled trial data on NAD+ precursors. The longest observational data comes from individuals self-experimenting, which has obvious limitations.

Questions that remain unanswered:

Efficacy in Healthy Adults

Many positive findings come from aged or metabolically unhealthy populations—where NAD+ levels are genuinely low and there's clear room for improvement. Whether healthy adults with presumably adequate NAD+ levels benefit meaningfully from supplementation is less clear.

The counterargument: even "healthy" adults over 40-50 likely have lower NAD+ than their younger selves, and maintaining youthful levels may provide benefit before overt dysfunction appears. But this remains somewhat speculative.

What David Sinclair's Critics Say

David Sinclair is the most prominent advocate for NAD+ supplementation, and his work has attracted both admirers and critics. Common criticisms include:

These criticisms don't invalidate the science, but they warrant healthy skepticism about the most optimistic claims. The truth is likely somewhere between "NAD+ supplementation is a game-changer for everyone" and "it's all hype."

9. Conclusion: A Balanced View

The NAD+ story represents both the promise and challenges of longevity science. The basic biology is compelling: NAD+ declines with age, this decline impairs critical cellular functions, and restoring NAD+ levels can reverse some age-related changes in animal models. Human evidence is accumulating, with several trials showing real benefits.

At the same time, we must acknowledge significant uncertainties: optimal dosing, long-term safety, efficacy in healthy populations, the cancer question, and tissue-specific effects all require more research. The field is moving fast, and recommendations may evolve.

A Framework for Decision-Making

For the evidence-conservative: Focus on exercise, fasting, and sleep—the proven NAD+-boosting interventions. Consider supplementation only if you have specific metabolic concerns (insulin resistance, low energy, signs of accelerated aging) and discuss with a healthcare provider.

For the informed biohacker: NAD+ precursors appear reasonably safe at standard doses and may provide meaningful benefits, particularly if you're over 40-50 or have metabolic dysfunction. Start with evidence-backed doses (250-500mg NMN or 300-600mg NR), monitor subjective effects, and consider adding synergistic interventions. Stay current with research as new data emerges.

For the investor/evaluator: The NAD+ market is real and growing, supported by legitimate science. However, be cautious about claims that outstrip evidence. The most valuable plays may be in clinical development of more targeted approaches (specific sirtuin activators, CD38 inhibitors, tissue-targeted delivery) rather than commodity precursor sales.

🎯 The Bottom Line

NAD+ supplementation is one of the more promising longevity interventions available today—grounded in solid biology and supported by growing human evidence. It's not a proven fountain of youth, and the most dramatic claims remain unsubstantiated in humans. But as part of a comprehensive approach to healthy aging—combined with exercise, appropriate nutrition, stress management, and medical oversight—it may help maintain cellular function and resilience as we age.

The science is young. Stay curious, stay skeptical, and stay engaged as new research emerges.

References

  1. Harden A, Young WJ. The alcoholic ferment of yeast-juice. Proc R Soc Lond B. 1906;78:369-375.
  2. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528-536.
  3. Gomes AP, Price NL, Ling AJ, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638.
  4. Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357.
  5. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141.
  6. Stein LR, Imai S. Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. EMBO J. 2014;33(12):1321-1340.
  7. Camacho-Pereira J, Tarragó MG, Chini CC, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through a SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127-1139.
  8. Mouchiroud L, Houtkooper RH, Moullan N, et al. The NAD+/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 2013;154(2):430-441.
  9. Kanfi Y, Naiman S, Amir G, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(7388):218-221.
  10. Bai P, Cantó C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab. 2012;16(3):290-295.
  11. Chini EN, Chini CCS, Espindola Netto JM, de Oliveira GC, van Schooten W. The pharmacology of CD38/NADase: an emerging target in cancer and diseases of aging. Trends Pharmacol Sci. 2018;39(4):424-436.
  12. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806.
  13. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
  14. Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022;8(1):5.
  15. Kim M, Seol J, Sato T, Fukamizu Y, Sakurai T, Okura T. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults. Nutrients. 2022;14(4):755.
  16. Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(1):47-57.
  17. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.
  18. Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28(7):1717-1728.e6.
  19. Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353.
  20. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-212.
  21. Avalos JL, Bever KM, Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD+ cosubstrate specificity of a Sir2 enzyme. Mol Cell. 2005;17(6):855-868.
  22. Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618-1626.
  23. de Guia RM, Agerholm M, Nielsen TS, et al. Aerobic and resistance exercise training reverses age-dependent decline in NAD+ salvage capacity in human skeletal muscle. Physiol Rep. 2019;7(12):e14139.
  24. Das A, Huang GX, Bonkowski MS, et al. Impairment of an endothelial NAD+-H2S signaling network is a reversible cause of vascular aging. Cell. 2018;173(1):74-89.e20.
  25. Yang H, Yang T, Baur JA, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 2007;130(6):1095-1107.
  26. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-342.
  27. Escande C, Nin V, Price NL, et al. Flavonoid apigenin is an inhibitor of the NAD+ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. 2013;62(4):1084-1093.
  28. Nacarelli T, Lau L, Fukumoto T, et al. NAD+ metabolism governs the proinflammatory senescence-associated secretome. Nat Cell Biol. 2019;21(3):397-407.
  29. Herranz D, Muñoz-Martin M, Cañamero M, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3.
  30. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471.
  31. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547.
  32. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.
  33. Cantó C, Menzies KJ, Auwerx J. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22(1):31-53.
  34. Zapata-Pérez R, Wanders RJA, van Karnebeek CDM, Houtkooper RH. NAD+ homeostasis in human health and disease. EMBO Mol Med. 2021;13(7):e13943.
  35. Tarragó MG, Chini CCS, Kanamori KS, et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD+ decline. Cell Metab. 2018;27(5):1081-1095.e10.
  36. Bonkowski MS, Sinclair DA. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol. 2016;17(11):679-690.
  37. Katsyuba E, Romani M, Hofer D, Auwerx J. NAD+ homeostasis in health and disease. Nat Metab. 2020;2(1):9-31.
  38. Chini CCS, Tarragó MG, Chini EN. NAD and the aging process: Role in life, death and everything in between. Mol Cell Endocrinol. 2017;455:62-74.
  39. Nadeeshani H, Li J, Ying T, Zhang B, Lu J. Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns. J Adv Res. 2022;37:267-278.
  40. Reiten OK, Wilvang MA, Mitchell SJ, Hu Z, Fang EF. Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing. Mech Ageing Dev. 2021;199:111567.
  41. Hong W, Mo F, Zhang Z, Huang M, Wei X. Nicotinamide mononucleotide: A promising molecule for therapy of diverse diseases by targeting NAD+ metabolism. Front Cell Dev Biol. 2020;8:246.
  42. Mehmel M, Jovanović N, Spitz U. Nicotinamide riboside—the current state of research and therapeutic uses. Nutrients. 2020;12(6):1616.
  43. Poljsak B, Milisav I. NAD+ as the link between oxidative stress, inflammation, caloric restriction, exercise, DNA repair, longevity, and health span. Rejuvenation Res. 2016;19(5):406-413.
  44. Johnson S, Imai S. NAD+ biosynthesis, aging, and disease. F1000Res. 2018;7:132.
  45. Fang EF, Lautrup S, Hou Y, et al. NAD+ in aging: molecular mechanisms and translational implications. Trends Mol Med. 2017;23(10):899-916.
  46. Yoshida M, Satoh A, Lin JB, et al. Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice. Cell Metab. 2019;30(2):329-342.e5.

Exploring longevity science? Continue with our guides.

Return to Soma

Share this article